Key Takeaways
- • The UK's Competition and Markets Authority has abandoned disqualification proceedings against Supraj Rajagopalan (former Cinven chief executive) and Alex Leslie (former Cinven colleague) over their roles in an NHS drug price-gouging scandal, closing a high-profile enforcement action against private equity leadership.
- • The CMA will proceed with a disqualification order against John Beighton, chief executive of the drug manufacturer owned by Cinven at the time of the illegal price increases, marking a narrowed but continued enforcement focus on operational management rather than fund-level leadership.
- • This decision follows a £52 million fine upheld against Cinven in 2025 for its role in illegal drug price increases to the UK's National Health Service, representing a significant antitrust loss for the private equity firm despite the dropped executive cases.
- • Rajagopalan and Leslie both departed their Cinven positions at the end of 2025, and both had contested the CMA's allegations; Rajagopalan characterized the closure as "the right outcome" while Leslie declined comment.
- • The case underscores ongoing regulatory scrutiny of private equity ownership structures and control, particularly in essential sectors like pharmaceuticals, but signals potential limits to antitrust enforcement against fund principals versus operational executives.
Summary
The UK Competition and Markets Authority has dropped its pursuit of disqualification orders against two senior Cinven executives—Supraj Rajagopalan and Alex Leslie—in connection with an NHS drug price-gouging scheme, according to Financial Times reporting. This reversal represents a significant narrowing of the regulator's enforcement action, which had initially targeted both fund leadership and operational management for their alleged involvement in illegal price increases.
The CMA's decision, announced on Wednesday, eliminates potential director bans against Rajagopalan, who served as Cinven's chief executive during the firm's acquisition and operation of the drug manufacturer in question, and Leslie, his former colleague at the buyout group. Both executives had contested the allegations when the CMA began weighing disqualification proceedings in October 2025. The regulator will, however, proceed with a competition disqualification order against John Beighton, the drug manufacturer's chief executive at the time of the illegal pricing activity, targeting operational rather than investment leadership.
This enforcement outcome concludes a multi-year regulatory saga. In 2025, a court upheld a £52 million fine against Cinven itself for orchestrating illegal price increases on a drug sold to the UK public health service—a substantial penalty that established the firm's corporate liability while leaving questions about individual accountability. Cinven had previously flagged to fund investors that Rajagopalan's position would be at risk if he faced disqualification, signaling the reputational and operational consequences such enforcement could trigger across the private equity industry.
Both executives departed their Cinven roles at the end of 2025. Rajagopalan stated he was "pleased to confirm that the investigation pertaining to me has been closed, with no action taken," characterizing the outcome as appropriate, while Leslie declined to provide commentary. The CMA's decision to pursue only the operational executive suggests a potential enforcement boundary: regulatory action targeting fund principals over portfolio company conduct may face higher evidentiary or legal thresholds than action against direct operational management, despite the investment firm's overall liability.
The CMA's decision, announced on Wednesday, eliminates potential director bans against Rajagopalan, who served as Cinven's chief executive during the firm's acquisition and operation of the drug manufacturer in question, and Leslie, his former colleague at the buyout group. Both executives had contested the allegations when the CMA began weighing disqualification proceedings in October 2025. The regulator will, however, proceed with a competition disqualification order against John Beighton, the drug manufacturer's chief executive at the time of the illegal pricing activity, targeting operational rather than investment leadership.
This enforcement outcome concludes a multi-year regulatory saga. In 2025, a court upheld a £52 million fine against Cinven itself for orchestrating illegal price increases on a drug sold to the UK public health service—a substantial penalty that established the firm's corporate liability while leaving questions about individual accountability. Cinven had previously flagged to fund investors that Rajagopalan's position would be at risk if he faced disqualification, signaling the reputational and operational consequences such enforcement could trigger across the private equity industry.
Both executives departed their Cinven roles at the end of 2025. Rajagopalan stated he was "pleased to confirm that the investigation pertaining to me has been closed, with no action taken," characterizing the outcome as appropriate, while Leslie declined to provide commentary. The CMA's decision to pursue only the operational executive suggests a potential enforcement boundary: regulatory action targeting fund principals over portfolio company conduct may face higher evidentiary or legal thresholds than action against direct operational management, despite the investment firm's overall liability.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.